BiotechTube
Home/Lumosa Therapeutics/Sheng‑Wen Yeh (Mimi)
SY

Sheng‑Wen Yeh (Mimi)

CFO

Lumosa Therapeutics

Therapeutic Areas

NeuroscienceOncologyCardiovascular

Lumosa Therapeutics Pipeline

DrugIndicationPhase
LT1001Postoperative PainMarket
LT3001Acute Ischemic StrokePhase 2
LT6001Neurological DisorderPre‑clinical
CS028Solid TumorPre‑clinical

Leadership Team at Lumosa Therapeutics

SW
Su‑Chi Wang
Chairperson
NL
Naomi Liu
General Manager
JK
June Kuo
Senior Director, Clinical Development
SL
Shu‑Hua Lee
Director, Product Development & IP
View full Lumosa Therapeutics profile